Profile
Claudia Ordonez worked as a Senior Medical Director at Vertex Pharmaceuticals from 2006 to 2012, then as a Senior Medical Director at Biogen from 2012 to 2015.
She was the Chief Medical Officer at Flatley Discovery Lab LLC from 2015 to 2018, and then Vice President at Akcea Therapeutics, Inc. from 2018 to 2019.
From 2019 to 2021, she served as the Chief Medical Officer at Keros Therapeutics, Inc. Ordonez received her undergraduate degree from the University of Maryland and her doctorate from the University of California, San Francisco.
Former positions of Claudia Ordonez
| Companies | Position | End |
|---|---|---|
| KEROS THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2021-07-29 |
| AKCEA THERAPEUTICS, INC. | Corporate Officer/Principal | 2019-08-31 |
Flatley Discovery Lab LLC
 Flatley Discovery Lab LLC Miscellaneous Commercial ServicesCommercial Services Flatley Discovery Lab LLC performs medical research activities. The non-profit company is based in Charlestown, MA. | Chief Tech/Sci/R&D Officer | 2018-09-30 |
| BIOGEN INC. | Chief Tech/Sci/R&D Officer | 2015-09-30 |
| VERTEX PHARMACEUTICALS INCORPORATED | Chief Tech/Sci/R&D Officer | 2012-05-31 |
Training of Claudia Ordonez
| University of Maryland | Undergraduate Degree |
| The University of California, San Francisco | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| VERTEX PHARMACEUTICALS INCORPORATED | Health Technology |
| BIOGEN INC. | Health Technology |
| KEROS THERAPEUTICS, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Flatley Discovery Lab LLC
Flatley Discovery Lab LLC Miscellaneous Commercial ServicesCommercial Services Flatley Discovery Lab LLC performs medical research activities. The non-profit company is based in Charlestown, MA. | Commercial Services |
Akcea Therapeutics, Inc.
 Akcea Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Akcea Therapeutics, Inc. is a biopharmaceutical company. It engages in the development and marketing of drugs globally to treat patients with rare and serious diseases using antisense technology. Its primary focus is developing TEGSEDI, a therapy that treats the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults. It also offers a mature pipeline of novel drugs including AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx, and AKCEA-APOCIII-LRx. The company was founded in December 2014 and is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- Claudia Ordonez
